Mizuho lowered shares of Chemours (NYSE:CC – Free Report) from a strong-buy rating to a hold rating in a research note released on Tuesday,Zacks reports.
Several other equities analysts have also issued reports on the company. Truist Financial lowered their price target on Chemours from $30.00 to $24.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Barclays began coverage on shares of Chemours in a research report on Monday. They set an “equal weight” rating and a $16.00 price objective on the stock. Zacks Research upgraded shares of Chemours from a “strong sell” rating to a “hold” rating in a research note on Thursday, September 10th. Weiss Ratings lowered shares of Chemours from a “sell (d)” rating to a “sell (d-)” rating in a research note on Thursday, August 6th. Finally, Morgan Stanley set a $18.00 target price on shares of Chemours in a report on Monday, August 10th. Three investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $18.09.
Read Our Latest Analysis on CC
Chemours Stock Performance
Chemours (NYSE:CC – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The specialty chemicals company reported $0.42 earnings per share for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.07). Chemours had a positive return on equity of 60.64% and a negative net margin of 5.00%. The business had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.65 billion. During the same quarter last year, the company posted ($2.54) EPS. Chemours’s revenue for the quarter was down 1.5% compared to the same quarter last year. Analysts expect that Chemours will post 0.84 earnings per share for the current year.
Chemours Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 15th. Stockholders of record on Friday, August 14th were given a dividend of $0.0875 per share. The ex-dividend date of this dividend was Friday, August 14th. This represents a $0.35 annualized dividend and a dividend yield of 2.7%. Chemours’s dividend payout ratio is presently -18.32%.
Insider Activity at Chemours
In other Chemours news, CEO Denise Dignam purchased 3,378 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were acquired at an average price of $14.95 per share, for a total transaction of $50,501.10. Following the purchase, the chief executive officer directly owned 339,916 shares of the company’s stock, valued at $5,081,744.20. The trade was a 1.00% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Shane Hostetter acquired 3,350 shares of the business’s stock in a transaction dated Thursday, August 6th. The shares were acquired at an average cost of $14.94 per share, with a total value of $50,049.00. Following the transaction, the chief financial officer owned 102,698 shares in the company, valued at approximately $1,534,308.12. This trade represents a 3.37% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders acquired 8,663 shares of company stock worth $130,601. 0.85% of the stock is owned by company insiders.
Institutional Trading of Chemours
Several hedge funds have recently bought and sold shares of the stock. Wedmont Private Capital bought a new stake in Chemours during the 3rd quarter worth approximately $145,000. Engineers Gate Manager LP lifted its holdings in Chemours by 24.6% during the second quarter. Engineers Gate Manager LP now owns 91,650 shares of the specialty chemicals company’s stock valued at $1,881,000 after purchasing an additional 18,106 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new position in Chemours during the second quarter valued at approximately $125,000. Nykredit A S bought a new position in shares of Chemours in the second quarter worth approximately $99,000. Finally, Corient Private Wealth LP boosted its position in shares of Chemours by 12.6% in the second quarter. Corient Private Wealth LP now owns 30,644 shares of the specialty chemicals company’s stock worth $629,000 after purchasing an additional 3,432 shares during the period. Institutional investors own 76.26% of the company’s stock.
More Chemours News
Here are the key news stories impacting Chemours this week:
- Positive Sentiment: BMO Capital reaffirmed its Buy rating, indicating that some analysts still see recovery potential in Chemours despite the recent weakness. BMO Capital reaffirms Buy rating
- Neutral Sentiment: Barclays initiated coverage at Equal Weight, while Mizuho maintained a Neutral rating but reduced its price target to $15 from $18. The new target still implies potential upside from recent trading levels, but the cut signals more cautious expectations. Mizuho downgrades Chemours
- Negative Sentiment: RBC Capital downgraded Chemours to Sector Perform from Outperform and cut its price target to $14 from $22, citing persistent TiO₂ weakness, soft chemical demand and potential headwinds in the Thermal & Specialized Solutions segment through year-end. RBC downgrades Chemours
- Negative Sentiment: Several law firms announced or promoted a securities-fraud class action filed against Chemours and certain officers. The case covers investors who purchased shares from February 20 through August 4, 2026, and alleges investors were harmed by disclosures concerning Opteon refrigerant aftermarket demand. The lead-plaintiff deadline is December 7, 2026. Although the allegations have not been proven, the litigation creates legal, financial and reputational risks. Chemours securities-fraud class action
About Chemours
The Chemours Company (NYSE: CC) is a global chemical company that develops, manufactures and distributes specialty chemical products used in a range of industrial and consumer applications. Its portfolio serves markets including coatings, plastics, automotive, refrigeration and air conditioning, electronics, telecommunications, energy, healthcare and general manufacturing.
Chemours operates through three primary business segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials.
Featured Articles
- Five stocks we like better than Chemours
- UnitedHealth Beats on Earnings, But Investors Question Growth Path
- Swarm Economics: Can XTEND AI Robotics Deliver at Scale?
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.
